Status and phase
Conditions
Treatments
About
The rationale for this study (IPV 002ABMG) is to evaluate and compare three doses of IPV, two doses of IPV plus one bOPV, and one dose of IPV plus two doses of bOPV in order to provide evidence for better immunization policy making in regions of the world that must switch to use of IPV/bOPV schedules in the 2014-2015 time frame. The goal is to identify the best option optimizing humoral immune responses, intestinal immunity and thereby prevent community transmission as well as preventing VAPP. Specifically, the study seeks to show that both of the sequential regimens are equivalent (not-inferior) to the 3-dose IPV regimen in the seroconversion rates to both type 1 and type 3 poliovirus such that not more than 10% of subjects fall below the 95% confidence interval observed for the 3-dose IPV alone regimen and the geometric mean titers (GMTs) are no more than 2/3 logs less than those for the 3-dose IPV regimen. In addition, the study will evaluate by a novel method (poliovirus shedding index), the adequacy of IPV vaccines in inducing intestinal immunity, specifically by reducing the shedding of poliovirus type 2 after an OPV challenge. The hypotheses of the study are:
In addition to these 3 hypotheses, the study will explore the following hypothesis:
• Co-administration of bOPV and rotavirus at 16 weeks of age (the second rotavirus dose) provides similar antirotavirus IgA seroconversion rates and GMCs compared to subjects receiving rotavirus vaccine together with IPV.
Full description
3.0 STUDY DESIGN This is a multicenter, randomized, unblinded study. Healthy infants attending the well-child care at outpatient clinics and due for their first dose of polio vaccines will be eligible for the study. Infants 8 wks ± 7 days of age will be randomized and allocated to three treatment groups.
4.0 STUDY POPULATION The study will be conducted in up to 7 "vacunatorios" in Chile. Parents or legal guardians of healthy infants, who are receiving well-child care at designated outpatient clinics, will be approached to participate in the study.
5.0 TREATMENT OF SUBJECTS 5.1 Vaccines The vaccines to be used in this study include bOPV, mOPV2, and IPV (see Section 14.2 for package inserts).
5.1.1 Bivalent Oral Polio Vaccine (bOPV) Produced by Sanofi Pasteur, Lyon, France, bivalent OPV vaccine contains types 1 and 3 polioviruses and it is indicated for supplementary immunization activities in children from 0 to 5 years of age to prevent or contain outbreaks caused by these 2 serotypes. The vaccine contains at least 6.0 log CCID50 of LS c2ab live attenuated polio virus type 1; and at least 5.8 log CCID50 Leon I2aIb strain of polio virus type 3. The vaccine dose is 2 drops (0.1 mL) using a multi-dose dropper vial, given directly into the mouth. The vaccine should be stored in a freezer at -20°C, and after thawing it can be stored up to 6 months at refrigerated temperatures of +2 to +8°C.
5.1.2 Monovalent Oral Polio Vaccine Type 2 (mOPV2) Monovalent OPV type 2 live attenuated poliomyelitis virus vaccine (mOPV2) is produced by Glaxo SmithKline, Rixensart, Belgium, as a sterile suspension of poliovirus serotype 2 for oral administration. Each dose (0.1 mL) contains not less than 105.0 CCID50 of the Sabin strain type 2 (P 712, Ch, 2ab). This will be the challenge OPV strain used to assess intestinal shedding and immunity. The vaccine should be stored in a freezer at -20°C, and after thawing it can be stored up to 6 months at refrigerated temperatures of +2 to +8°C.
5.1.3 Inactivated Polio Vaccine (IPV) Inactivated poliovirus vaccine is produced by Sanofi-Pasteur as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3). It also contains 0.5% of 2-phenoxyethanol and a maximum of 0.02% of formaldehyde as preservatives. It may also contain 5 ng of neomycin, 200 ng of streptomycin, and 25 ng of polymixin B as residuals of the vaccine production. The vaccine does not contain Thimerosal. The vaccine should be kept refrigerated at +2 to +8°C, and should never be frozen. The dose of IPV vaccine should be 0.5 mL administered intramuscularly in the anterolateral aspect of the thigh.
5.2 Vaccine Intervals and Administration All polio vaccine doses should be administered at least 4 weeks or more apart. For IPV, the administration site is restricted to the anterolateral aspect of the left thigh.
Prior to an injection of any vaccine, all known precautions should be taken to prevent adverse reactions. This includes a review of the potential participant's history with respect to possible allergic reactions to the vaccine or similar vaccines. Epinephrine Injection (1:1000) and other appropriate agents should be available to control immediate allergic reactions. Health-care providers should obtain the previous immunization history of the subject, and inquire about the current health status of the subject.
Infants participating in the study will be provided the recommended vaccines aside from polio vaccine as per the National Immunization Schedule of Chile (DTPw/HBV/Hib, S. pneumoniae vaccine).
In addition, a 2-dose (RotarixTM) oral rotavirus vaccine will be offered during the study at 8 weeks and 16 weeks of age.
Serology Testing
Rational for each blood sample: After thorough discussions on the minimum number of serum samples required to obtain valid answers to our hypothesis, the research group has arrived to the following:
A total of 4 blood samples will be collected for each study subject. A maximum of 3 mL will be obtained by heel stick or venipuncture methods. Each blood sample will be transported within 24 hours in appropriate cold chain conditions to the "Central Study Laboratory" at the Microbiology and Mycology Program, Institute of Biomedical Sciences, Faculty of Medicine, University of Chile. Sera will be obtained and 2 aliquots will be placed into cryovials, labeled with linked coding, and stored in a -20°C freezer. One aliquot will be shipped in appropriate cold chain conditions to the Polio and Picornavirus Laboratory Branch, Center for Disease Control and Prevention. The second aliquot will be left on repository storage at the study center.
Sera will be processed following a standard protocol (see Section 14.1). Neutralizing antibodies against polioviruses 1, 2, and 3 will be determined using a sero-neutralization assay. The laboratory will be blinded with regard to the vaccination status of individuals contributing particular specimens, ensuring the integrity of the study. After successful completion of testing, duplicate specimens will be destroyed. Authorized specimens assays are only for antibody levels to valences included in the study vaccines. Should the case arise, the use of these specimens for any other assay will require the approval of the study Sponsor and the Principal Investigator, as well as Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approval, as per applicable rules and regulations.
Baseline sera and sera obtained at 28 weeks will be processed for antirotavirus IgA concentration as previously described at Glaxo SmithKline laboratories (26).
5.3 Stool Samples for Poliovirus "Shedding Index" determination Stool samples (5 to 10 grams) will be collected at 5 times for each subject, using WHO approved protocols and kits, and transported and stored following the WHO procedures for detection of polioviruses. Fresh stools will be collected unmixed with urine in a screw-top container, placed in a cold box with frozen ice packs, and transported to the designated laboratory for storage in a freezer at -20°C. A log book of collected and stored samples will be kept by the study personnel. Stool samples will be used later to determine the excretion of polioviruses as per protocol (Section 14.1). Samples will be sent in batches to the reference laboratory for poliovirus culture.
5.4 Medications/Treatments Permitted (including rescue medication) and not Permitted Before and/or During the Trial There will be no restrictions in using medications/treatments except for the following conditions: primary immune deficiency or immune deficiency subsequent to treatment, leukemia, lymphoma or advanced malignancy in the subject to be vaccinated or his/her close contact. Only medications to treat SAEs or IMEs will be documented in eCRF. All other medications will be captured and recorded in the source document at the investigators discretion at the investigational site.
5.5 Subject Compliance Subjects are required to abide by scheduled visits and the vaccine schedule.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
570 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal